NetworkNewsBreaks – Lexaria Bioscience Corp.’s
Post# of 721
(Total Views: 172)
Posted On: 04/29/2019 2:51:04 PM
NetworkNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Innovative Technology Improves Delivery of Nicotine, Cannabinoids
Biotechnology company and drug-delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed and out-licenses its pioneering-drug delivery platform DehydraTECH(TM), which improves the speed, taste and delivery of bioactive compounds, including nicotine and cannabinoids. A recent article discussing the company reads, “Furthermore, the DehydraTECH drug delivery platform increases bio-absorption by up to 10 times and lessens the time of onset, with effects being felt within 15 to 20 minutes, as compared to 60 to 120 minutes without the platform. In addition, the technology is patent protected for cannabidiol (CBD) and all other nonpsychoactive cannabinoids. Patents are also granted for THC (tetrahydrocannabinol), other psychoactive compounds and NSAIDs (nonsteroidal, anti-inflammatory drugs), as well as nicotine and other molecules. . . . Lexaria Bioscience has partnered with one of the world’s largest tobacco companies to fund the research and development of the DehydraTECH technology for oral nicotine. Through wholly owned subsidiary Lexaria Nicotine LLC, Lexaria is working to propel innovation in oral, reduced-risk nicotine consumer products utilizing DehydraTECH (http://nnw.fm/OmL1K).”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Biotechnology company and drug-delivery platform innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has developed and out-licenses its pioneering-drug delivery platform DehydraTECH(TM), which improves the speed, taste and delivery of bioactive compounds, including nicotine and cannabinoids. A recent article discussing the company reads, “Furthermore, the DehydraTECH drug delivery platform increases bio-absorption by up to 10 times and lessens the time of onset, with effects being felt within 15 to 20 minutes, as compared to 60 to 120 minutes without the platform. In addition, the technology is patent protected for cannabidiol (CBD) and all other nonpsychoactive cannabinoids. Patents are also granted for THC (tetrahydrocannabinol), other psychoactive compounds and NSAIDs (nonsteroidal, anti-inflammatory drugs), as well as nicotine and other molecules. . . . Lexaria Bioscience has partnered with one of the world’s largest tobacco companies to fund the research and development of the DehydraTECH technology for oral nicotine. Through wholly owned subsidiary Lexaria Nicotine LLC, Lexaria is working to propel innovation in oral, reduced-risk nicotine consumer products utilizing DehydraTECH (http://nnw.fm/OmL1K).”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼